On June 14, 2022, the 6th Future Healthcare Top 100 Summit officially kicked off as an online cloud event. Spanning five days with 22 thematic forums, the summit gathered industry leaders online to share insights and explore the innovative development of China’s healthcare industry. During the conference, the highly anticipated “Future Healthcare Top 100 List” was officially released. Recognized for its robust independent R&D capabilities and high-quality innovative product pipeline, Andao Pharma was successfully selected into the “China Innovative Biopharmaceutical Top 100”.

Launched in 2015 by VB100, 36Kr Venture Capital and Eggshell Research Institute, the Future Healthcare Top 100 List is China’s first authoritative innovation ranking focusing on unlisted healthcare enterprises. It aims to identify outstanding innovative medical enterprises that represent the future of the industry and discover the core driving forces of China’s healthcare sector. After seven years of iteration and optimization, the evaluation system has been widely recognized and highly valued by the industrial and capital communities, serving as a key benchmark for assessing enterprises’ innovation strength and growth potential.

The 2022 ranking was comprehensively evaluated based on capital market attention, supplemented by media exposure, annual corporate performance data and industry development prospects. Over 1,300 enterprises across four major sectors—medical devices, biopharmaceuticals, digital healthcare and medical services—were assessed, and only the most representative, high-growth and high-potential innovative companies were shortlisted for the TOP 100 list. This honor fully validates Andao Pharma’s outstanding R&D capabilities, industrialization potential and long-term development value.

This marks Andao Pharma’s first inclusion in the China Innovative Biopharmaceutical Top 100 list. Dr. Liu Dong, Founder, Chairman and CEO of Andao Pharma, expressed great delight and gratitude for the achievement. He stated that this recognition stems from the company’s long-term commitment to global innovative drug R&D, the development of an international talent team, and the strong support from all strategic partners.

Since its founding, Andao Pharma has focused on two critical therapeutic areas—nephrology and oncology—dedicated to developing original Class 1 innovative drugs to address unmet clinical needs and global medical challenges affecting human health and quality of life. The company’s core pipeline features two proprietary global innovative drug candidates: AND017, a novel Class 1 drug for renal anemia, and AND019, an innovative therapy for breast cancer, with worldwide intellectual property rights secured for both assets.

AND017 is developed based on the groundbreaking oxygen-sensing regulatory mechanism honored with the2019 Nobel Prize in Physiology or Medicine, laying a solid theoretical foundation for its clinical development and commercialization. Furthermore, Nobel Laureate Professor Gregg L. Semenza has joined the company as Chair of the Scientific Advisory Board, empowering Andao Pharma to build a world-leading drug discovery platform targeting oxygen regulatory signaling pathways. AND019, a third-generation oral breast cancer candidate, has demonstrated superior efficacy and safety profiles compared with existing therapies in preclinical studies, with the potential to overcome clinical drug resistance and deliver new treatment options for breast cancer patients. Currently, AND017 and AND019 are advancing steadily in global multi-center Phase II and Phase I clinical trials, respectively.

Benefiting from its global R&D system, international team building and steady industrialization progress, Andao Pharma has gained wide recognition from the capital market. The company completed Series A and Series B financing rounds in 2019 and 2021, raising a total of USD 85 million. The Series A round was exclusively invested by Decheng Capital, a U.S.-based professional biotech investment institution, while the Series B round was co-led by leading domestic investors Northern Light Venture Capital and Gaorong Capital. The successive investments fully reflect the confidence of global and domestic capital in the company’s core technologies, innovative achievements and management team.

Upholding the core philosophy of “Respecting Science, Cherishing Life, and Benefiting Patients”, Andao Pharma will continue to focus on innovative drug research in nephrology and oncology. The company will keep breaking through technical barriers, accelerate the clinical transformation of core pipelines, support the high-quality development of China’s innovative pharmaceutical industry, and strive to deliver safer and more effective original therapeutic solutions for global patients.